These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 4413659)

  • 1. Heparin half-life in normal and impaired renal function.
    Perry PJ; Herron GR; King JC
    Clin Pharmacol Ther; 1974 Sep; 16(3):514-9. PubMed ID: 4413659
    [No Abstract]   [Full Text] [Related]  

  • 2. Heparin elimination and hemostasis in hemodialysis.
    Wilhelmsson S; Lins LE
    Clin Nephrol; 1984 Dec; 22(6):303-6. PubMed ID: 6525772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letter: Heparin half-life in normal and impaired renal function.
    Ignoffo RJ
    Clin Pharmacol Ther; 1975 Feb; 17(2):249-51. PubMed ID: 1122679
    [No Abstract]   [Full Text] [Related]  

  • 4. [Individual dosage schedule of heparin therapy in chronic hemodialysis by analytic studies of blood coagulation].
    Gläser V; Anstadt M
    Z Urol Nephrol; 1990 Mar; 83(3):133-40. PubMed ID: 2356667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of renal failure and hemodialysis on cephacetrile pharmacokinetics.
    Nissenson AR; Levin NW; Parker RH
    Clin Pharmacol Ther; 1972; 13(6):887-94. PubMed ID: 5081601
    [No Abstract]   [Full Text] [Related]  

  • 6. Monitoring heparin therapy in hemodialysis. A report on the activated whole blood coagulation time tests.
    Congdon JE; Kardinal CG; Wallin JD
    JAMA; 1973 Dec; 226(13):1529-33. PubMed ID: 4800932
    [No Abstract]   [Full Text] [Related]  

  • 7. Flucytosine kinetics in subjects with normal and impaired renal function.
    Cutler RE; Blair AD; Kelly MR
    Clin Pharmacol Ther; 1978 Sep; 24(3):333-42. PubMed ID: 688726
    [No Abstract]   [Full Text] [Related]  

  • 8. [Measurement of activated whole blood coagulation as a control parameter for heparin dosage in hemodialysis].
    Kraatz G; Lopot F
    Z Urol Nephrol; 1984 Aug; 77(8):465-71. PubMed ID: 6495895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study of renal function in renal insufficiency. I. Renal function of the patients under chronic hemodialysis].
    Kawamura J; Okabe T; Yamashita A; Sawanishi K; Katõ T
    Hinyokika Kiyo; 1971 Mar; 17(3):157-86. PubMed ID: 5103947
    [No Abstract]   [Full Text] [Related]  

  • 10. Hemodialysis without heparin infusion using Cordis Dow 3500 hollow fiber.
    Raja R; Kramer M; Rosenbaum JL; Bolisay C; Krug M
    Proc Clin Dial Transplant Forum; 1980; 10():39-42. PubMed ID: 7346852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haemostasis parameters behaviour during haemodialysis without anticoagulants.
    Casati S; Moia M; Graziani G; Cantaluppi A; Mannucci PM; Ponticelli C
    Life Support Syst; 1983; 1 Suppl 1():144-7. PubMed ID: 6336396
    [No Abstract]   [Full Text] [Related]  

  • 12. The kinetics of heparin.
    Estes JW
    Ann N Y Acad Sci; 1971 Jul; 179():187-204. PubMed ID: 5285374
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of renal failure on blood levels of cimetidine.
    Ma KW; Brown DC; Masler DS; Silvis SE
    Gastroenterology; 1978 Feb; 74(2 Pt 2):473-7. PubMed ID: 620915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low molecular weight heparin half life is prolonged in haemodialysed patients.
    Goudable C; Ton That H; Damani A; Durand D; Caranobe C; Sié P; Boneu B
    Thromb Res; 1986 Jul; 43(1):1-5. PubMed ID: 3726807
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetic aspects of digoxin in patients with terminal renal failure. I. Off dialysis.
    van der Vijgh WJ
    Int J Clin Pharmacol Biopharm; 1977 Jun; 15(6):249-54. PubMed ID: 881276
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics of ceftazidime in patients with renal insufficiency and in those undergoing hemodialysis.
    Ohkawa M; Nakashima T; Shoda R; Ikeda A; Orito M; Sawaki M; Sugata T; Shimamura M; Hirano S; Okumura K
    Chemotherapy; 1985; 31(6):410-6. PubMed ID: 3908006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated coagulation time test: a convenient monitor of heparinization for dogs used in cardiovascular research.
    Wilkerson RD; Conran PB; Greene SL
    Lab Anim Sci; 1984 Feb; 34(1):62-5. PubMed ID: 6716959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum half-lives and elimination rates of a new semi-synthetic cephalosporin, cephacetrile, in nephrectomized patients and in patients with impaired or normal renal function.
    Reutter F; Maurice NP
    Arzneimittelforschung; 1974 Sep; 24(9b):1466-8. PubMed ID: 4479804
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetics and response to diazoxide in renal failure.
    Pearson RM
    Clin Pharmacokinet; 1977; 2(3):198-204. PubMed ID: 328207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antithrombin III and heparinemia in patients on hemodialysis].
    Nagami AE; Sesin AM; Nattero GN
    Rev Fac Cien Med Univ Nac Cordoba; 1988; 46(1):23-6. PubMed ID: 3273332
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.